{"id":"consolidation-sintilimab","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Immune-related pneumonitis"},{"rate":null,"effect":"Immune-related hepatitis"},{"rate":null,"effect":"Immune-related colitis"},{"rate":null,"effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL4297829","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sintilimab binds to programmed death receptor 1 (PD-1) on T cells, preventing interaction with PD-L1 and PD-L2 ligands expressed by tumor cells. This blockade restores anti-tumor immune responses by reactivating exhausted T cells. In consolidation therapy, it is used after initial treatment to maintain disease control and improve long-term outcomes.","oneSentence":"Sintilimab is a monoclonal antibody that blocks PD-1 on immune cells, allowing them to recognize and attack cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:07:24.517Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Consolidation therapy in non-small cell lung cancer (NSCLC) following concurrent chemoradiotherapy"}]},"trialDetails":[{"nctId":"NCT07416890","phase":"PHASE2","title":"Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2026-02-10","conditions":"Pirtobrutinib, Sintilimab, Central Nervous System Lymphoma","enrollment":24},{"nctId":"NCT07306663","phase":"PHASE3","title":"Sintilimab Combined With Chemotherapy Induction Therapy Followed by CCRT vs. CCRT for Esophageal Cancer: A Randomized Controlled Phase Ⅲ Clinical Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2021-06-01","conditions":"Esophageal Cancer","enrollment":242},{"nctId":"NCT07035860","phase":"","title":"Efficacy and Safety of Chemoimmunotherapy and Carbon Ion Radiotherapy in Unresectable Locally Advanced Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Ji Yongling","startDate":"2025-06-16","conditions":"Carbon Ion Radiotheray","enrollment":34},{"nctId":"NCT06916117","phase":"PHASE2","title":"Neoadjuvant Chemo-immunotherapy Followed by Concurrent Chemoradiotherapy and Immunotherapy in LACC","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-04-05","conditions":"Locally Advanced Cervical Cancer","enrollment":30},{"nctId":"NCT04212598","phase":"PHASE2","title":"The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer","status":"COMPLETED","sponsor":"Wuhan University","startDate":"2020-08-03","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":40},{"nctId":"NCT06295926","phase":"PHASE2","title":"Serplulimab Combined With CCRT for LS-SCLC.","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-04-04","conditions":"Small Cell Lung Cancer","enrollment":96},{"nctId":"NCT06468644","phase":"PHASE2","title":"Phase II Study of Different Doses of Radiotherapy Combined With Sintilimab in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2024-06-17","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":60},{"nctId":"NCT06084897","phase":"PHASE2","title":"Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-10-16","conditions":"Esophageal Neoplasm Metastatic, Esophageal Cancer Stage IVb","enrollment":120},{"nctId":"NCT06342167","phase":"PHASE2","title":"Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-03-14","conditions":"Locally Advanced Esophageal Squamous Cell Carcinoma, Sintilimab, Radiotherapy","enrollment":57},{"nctId":"NCT06401447","phase":"NA","title":"TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-12-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":50},{"nctId":"NCT06364826","phase":"PHASE2","title":"Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-04-22","conditions":"Nasopharyngeal Carcinoma","enrollment":60},{"nctId":"NCT04514835","phase":"PHASE2","title":"A Phase Ⅱ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCC","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2021-12-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":44},{"nctId":"NCT04023916","phase":"PHASE2","title":"Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2019-12-01","conditions":"Diffuse Large B-Cell Lymphoma, Sintilimab, TP53 Mutation","enrollment":30},{"nctId":"NCT03884192","phase":"PHASE3","title":"Consolidation Sintilimab After Concurrent Chemoradiation in Patients With Unresectable Stage III NSCLC","status":"UNKNOWN","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2018-12-12","conditions":"Carcinoma, Non-Small Cell Lung","enrollment":162}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Consolidation Sintilimab","genericName":"Consolidation Sintilimab","companyName":"Shandong Cancer Hospital and Institute","companyId":"shandong-cancer-hospital-and-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sintilimab is a monoclonal antibody that blocks PD-1 on immune cells, allowing them to recognize and attack cancer cells. Used for Consolidation therapy in non-small cell lung cancer (NSCLC) following concurrent chemoradiotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}